TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01364298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin/B-complex
Description: Gabapentin/B-complex (Gavindo®) tablet will be administered orally at an initial dose of 300 milligram per day (mg/day) on Day 1, followed by 600 mg/day (one 300 milligram \[mg\] tablet every 12-hour) on Day 2, then 900 mg/day (one 300 mg tablet every 8-hour) on Day 7, then 1800 mg/day (two 300 mg tablets every 8-hour) on Day 21, then 2700 mg/day (three 300 mg tablets every 8-hour) on Day 35, and finally 3600 mg/day (four 300 mg tablets every 8-hour) on Days 56 and 84. Maximum dose allowed will be 3600 mg/day. The total duration of treatment will be 84 days (12 weeks).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin (Lyrica®) capsule will be administered orally at an initial dose of 150 mg/day (one 75 mg capsule every 12-hour) from Day 1 to 7, followed by 300 mg/day (one 150 mg capsule every 12-hour) on Day 7, then 600 mg/day (two 150 mg capsule every 12-hour) on Days 21, 35, 56 and 84. Maximum dose allowed will be 600 mg/day. The total duration of treatment will be 84 days (12 weeks).
Study: NCT01666925

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 ME-TRAP / MVA ME-TRAP prime-boost immunisation
Description: ChAd63 ME-TRAP: 5 x 10\^10vp MVA ME-TRAP: 2 x 10\^8 pfu

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabies vaccine
Description: 2 x 2.5IU Verorab
Study: NCT03614871

Intervention type: OTHER
Intervention: Epidemiological study
Study: NCT00871598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTT1023
Description: intravenous, three infusions over three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTT1023
Description: intravenous, three infusions over three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTT1023
Description: intravenous, three infusions over three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTT1023
Description: intravenous, three infusions over three weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous, three infusions over three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTT1023
Description: Test challenge
Study: NCT02253654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Description: Administered intravenously (IV) three times a week (TIW) by appropriately trained healthcare professionals during hemodialysis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin alfa
Description: Administered intravenously (IV) three times a week (TIW) by appropriately trained healthcare professionals during hemodialysis.
Study: NCT02954120

Intervention type: OTHER
Intervention: no intervention provided

Intervention type: OTHER
Intervention: no intervention provided

Intervention type: OTHER
Intervention: no intervention provided

Intervention type: OTHER
Intervention: no intervention provided
Study: NCT03077828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT00405483

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard exposure
Description: Minimal invasive vs standard exposure of the joint is the difference between a small incision, smaller equipment for less tissue damage vs large incision (standard is greater than 10cm)and subsequent more tissue damage.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally Invasive
Description: Minimally invasive surgical technique (minimal incision)
Study: NCT01492712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Patients in the low-high-low group will receive an infusion of propofol with an initial blood target concentration of 2 mcg/ml. After 15 minutes the target will be increased to 5 mcg/ml and after a further 15 minutes the target will be reduced back to 2 mcg/ml for a further 15 to 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Patients in the high-low-high group will receive an infusion of propofol with an initial blood target concentration of 5 mcg/ml. After 15 minutes the target will be reduced to 2 mcg/ml and after a further 15 minutes the target will be increased back to 5 mcg/ml for a further 15 to 30 minutes.
Study: NCT00868114

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH-pulsed autologous dendritic cell vaccine
Description: 5 X10e7 KLH-pulsed autologous dendritic cell vaccine once weekly times three weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH-pulsed autologous dendritic cell vaccine
Description: 5 X10e7 KLH-pulsed autologous dendritic cell vaccine once weekly times three weeks
Study: NCT01315301

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of different treatment strategies
Description: 600 mg efavirenz based HAART initiated one week after starting rifampicin based short course anti tuberculosis treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of different treatment strategies
Description: 600 mg efavirenz based HAART initiated four weeks after starting rifampicin based short course anti tuberculosis treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of different treatment strategies
Description: 600 mg efavirenz based HAART initiated eight weeks after starting rifampicin based short course anti tuberculosis treatment.
Study: NCT05602935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg, intravenously, d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOX
Description: SOX (S-1: 40\~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery
Study: NCT04649801

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atrial fibrillation ablation
Description: Catheter ablation
Study: NCT04093726

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lollipop
Description: chewing lollipop for 20min
Study: NCT01298154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Dietary treatments with beverages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Dietary treatments with beverages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Dietary treatments with beverages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Dietary treatments with beverages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Dietary treatments with beverages
Study: NCT04331119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: SecuraBio will supply duvelisib

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draw
Description: -Prior to transplant, cycle 1 day 1 of duvelisib, and at the time of all imaging studies
Study: NCT01593150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pradaxa
Description: Pradaxa for 3 weeks prior to DC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TEE
Description: Transesophageal echo to exclude LAA thrombus, followed by early DC.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compare TEE guided cardioversion to Dabigatran + DC cardioversion
Description: compare the two groups, TEE followed by early DC cardioversion with Dabigatran for 3 weeks followed by DC cardioversion.
Study: NCT03938298

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS (vaporizer/e-cig) and smoking cessation counseling
Description: Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive standards of care, i.e. smoking cessation counseling and encouragement to use NRT. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date and again at week 1, 2, 4 and 8 after the target quit date. All participants will be followed over a 6-month period. After 6 months, participants will be asked to come to a final clinical visit.~PFT and MBW will be performed at baseline and after the 6 months follow-up period in all participants of the substudy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling
Description: Participants in the control group will receive standard of care only, i.e. i.e. smoking cessation counseling and encouragement to use NRT. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date and again at week 1, 2, 4 and 8 after the target quit date. All participants will be followed over a 6-month period. After 6 months, participants will be asked to come to a final clinical visit.~PFT and MBW will be performed at baseline and after the 6 months follow-up period in all participants of the substudy.
Study: NCT02861352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet zinc
Description: 4 mg zinc, as zinc sulfate, was added to a controlled diet; 25 mg supplemental zinc was given during the final recovery period when an ad lib diet was consumed
Study: NCT01890330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Canola Oil 25 g/d
Description: Daily consumption of food items containing traditional canola oil (25 g/d) for 12 weeks.
Study: NCT02172664

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Self etch enamel etching
Description: The adhesive will be applied according to manufacturer's instructions. If the lesion is greater than 2 mm in any dimension, incremental placement of Tetric EvoCeram composite (Ivoclar Vivadent) will occur with the first increment being placed against enamel.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self etch enamel etching
Description: The adhesive will be applied according to manufacturer's instructions. If the lesion is greater than 2 mm in any dimension, incremental placement of Tetric EvoCeram composite (Ivoclar Vivadent) will occur with the first increment being placed against enamel.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: selective etch protocol
Description: Total Etch (37% phosphoric acid; Ivoclar) will be placed on the enamel margin with no intentional placement on the dentin within the lesion. The adhesive will then be applied as instructed by the manufacturer. Tetric EvoCeram composite will be placed, light-cured, finished, and polished in the same manner as for the self-etch group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: selective etch protocol
Description: Total Etch (37% phosphoric acid; Ivoclar) will be placed on the enamel margin with no intentional placement on the dentin within the lesion. The adhesive will then be applied as instructed by the manufacturer. Tetric EvoCeram composite will be placed, light-cured, finished, and polished in the same manner as for the self-etch group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Adhese Universal
Description: the universal adhesive, Adhese Universal , will be applied to the selected tooth following manufacturer instructions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adhese Universal
Description: the universal adhesive, Adhese Universal , will be applied to the selected tooth following manufacturer instructions
Study: NCT03432104

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oxxynea®
Description: Oxxynea® is a blend of polyphenol-rich extracts from olive, grape, pomegranate, green tea, grapefruit, orange and blueberry. Dosage is 1 x 450 mg-capsule.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oxxynea®
Description: Oxxynea® is a blend of polyphenol-rich extracts from olive, grape, pomegranate, green tea, grapefruit, orange and blueberry. Dosage is 1 x 450 mg-capsule.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo product is 100% maltodextrin. Dosage is 1 x 450 mg-capsule of identical appearance than the verum capsule.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo product is 100% maltodextrin. Dosage is 1 x 450 mg-capsule of identical appearance than the verum capsule.
Study: NCT04060667

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Wireless physiologic monitoring
Description: The intervention in this study is the use of a wireless monitor to perform physiologic monitoring of women undergoing emergency cesarean delivery for the first 24 hours after completion of the cesarean and send alerts to responding clinicians should vital signs fall out of a pre-specified range.
Study: NCT00957801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone injection
Description: 100 mg single IM injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone injection
Description: 100 mg single IM injection
Study: NCT02759900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indirect non-thermal, atmospheric plasma to treat hair loss and acne
Description: A compound of non-thermal, atmospheric plasma and medium is delivered to or generated at the target area. Plasma is generated using either microsecond dielectric barrier discharge plasma device or PiezoBrush (a helium jet plasma). The medium is an aqueous alcohol solution
Study: NCT02186951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin - clavulanic acid
Description: Amoxicillin-clavulanic acid 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
Study: NCT01601587

Intervention type: OTHER
Group type: OTHER
Intervention: A psychoeducational group intervention.
Description: The intervention is an introduction seminar. It will be held over FOUR hours. Up to 15 patients can participate in each seminar. The content of the was developed based on study 1. The presentation about available treatment options and patient's rights are made by multi professional health personnel and user representatives. More specifically, this will be done under the following topics:~1. What is mental health?~2. Treatment options: orientation about individual and group based treatment modalities.~3. Former patients experience with their own treatment, self-help and participation.~4. How to influence and participate actively in the treatment and patient rights.~5. What can I do while I wait for treatment and where can I otherwise do to avoid aggravation?
Study: NCT04208022

Intervention type: OTHER
Intervention: Respiratory evaluation
Description: Hypermobility and Respiratory evaluation

Intervention type: OTHER
Intervention: Respiratory evaluation
Description: Hypermobility and Respiratory evaluation
Study: NCT03808662

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Sterotactic Body Radiotherapy/SBRT
Description: In general, it is recommended using 9-10 Gy x 3 or 10 Gy x 5 fractions given every other day. Physicians should try to give the highest BED whenever possible while respecting normal tissue tolerance. All lesions are recommended to receive a biologically effective dose (BED) of 60 Gy or higher (BED10≥70), assuming α/β ratio of 10 and using the linear-quadratic model: BED = nd x \[1 + d/(α/β)\] where n is number of fractions and d is dose per fraction. Sometimes BED ≥80 Gy is preferred, with lower doses ≥50 Gy allowed at the discretion of the treating physician for concerns about normal tissue toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care per physician discretion
Study: NCT00493766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Study: NCT02352948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736 (durvalumab)
Description: MEDI4736 (durvalumab) treatment by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736 (durvalumab)
Description: MEDI4736 (durvalumab) treatment by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Vinorelbine by intravenous infusion. Administered at a dose of 30 mg/m2 iv on Days 1, 8, 15 and 22 of a 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Vinorelbine by intravenous infusion. Administered at a dose of 30 mg/m2 iv on Days 1, 8, 15 and 22 of a 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine by intravenous infusion. Administered at a dose of 1000 mg/m2 iv over 30 minutes on Days 1, 8, and 15 of a 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine by intravenous infusion. Administered at a dose of 1000 mg/m2 iv over 30 minutes on Days 1, 8, and 15 of a 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Erlotinib administered at a dose of 150 mg once daily as a tablet for oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Erlotinib administered at a dose of 150 mg once daily as a tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4)
Description: MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4) treatment by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tremelimumab (anti-CTLA4)
Description: tremelimumab (anti-CTLA4) treatment by intravenous infusion
Study: NCT03712917

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Greater Occipital Nerve Block
Description: An enjection to paralyze the occipital nerve.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: An antiepileptic agent used for migraine prophylaxis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flunarizine
Description: A calcium overload blocker agent used for migraine prophylaxis.
Study: NCT01094080

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard infant formula
Description: infants are fed a commercial formula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: modified infant formula
Description: the modified infant formula has a different protein content than the standard formula and long chain polyunsaturated fatty acids are added

Intervention type: OTHER
Group type: OTHER
Intervention: breast milk
Description: infants are breast fed
Study: NCT03362554

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Controlled diet and exercise.
Description: The intervention will involve 3 weeks of a diet and exercise program designed to cause a net energy decrease of 7000 kcal/week compared to habitual behaviour. This will be achieved through:~* Five exercise sessions per week at 70% VO2 max, using 400 kcal per session.~* Reduction of their standard diet by 5000 kcal per week~Before and after this intervention period participants will take part in a trial day which includes measurement of body composition (using DEXA) and blood sugar control (oral glucose tolerance test). Samples of blood, adipose, skeletal muscle and faeces will also be taken.
Study: NCT00818948

Intervention type: DRUG
Group type: OTHER
Intervention: AMG 811
Description: Part A of the study will enroll SLE without GN (non-renal) subjects into 3 cohorts (6 AMG 811: 2 placebo). All subjects will receive a dose of AMG 811 or placebo every 4 weeks beginning with day 1 (D1) for a total of 3 injections. Subjects will be followed through to study day 197, 5 months from the last dose of study medication. Part B of the study will enroll SLE subjects with GN into Cohorts 4, 5 and 6 (6 AMG 811: 2 placebo). Similar to Part A, subjects in Cohorts 4, 5 and 6 will be dosed every 4 weeks with AMG 811 or placebo for a total of 3 injections followed by a 5 month follow-up period. For Cohort 6, subjects will be followed by a 6 month follow-up period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG 811
Description: Part A of the study will enroll SLE without GN (non-renal) subjects into 3 cohorts (6 AMG 811: 2 placebo). All subjects will receive a dose of AMG 811 or placebo every 4 weeks beginning with day 1 (D1) for a total of 3 injections. Subjects will be followed through to study day 197, 5 months from the last dose of study medication. Part B of the study will enroll SLE subjects with GN into Cohorts 4, 5 and 6 (6 AMG 811: 2 placebo). Similar to Part A, subjects in Cohorts 4, 5 and 6 will be dosed every 4 weeks with AMG 811 or placebo for a total of 3 injections followed by a 5 month follow-up period. For Cohort 6, subjects will be followed by a 6 month follow-up period.
Study: NCT00093054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry juice
Description: TID dosage for UTI treatment

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cranberry juice
Description: TID placebo dosage to match active comparator
Study: NCT04817280

Intervention type: OTHER
Intervention: Ice Swimming
Description: The intervention is not made in the course of a research study. Ice swimming has been introduced earlier by a given group. The group was made up of people who already swim in ice.
Study: NCT00765193

Intervention type: OTHER
Group type: OTHER
Intervention: Inspection of covered areas
Description: Clinicans performed a two-step examination for skin cancer, with clinical examination of individual lesions was aided by the use of dermoscopy, as needed. In the first step, physicians performed inspection of problem areas and uncovered areas only, and lesions suggestive of melanoma or non-melanoma skin cancer were noted. In the second step, TBSE was performed. Following both examinations, lesions suggestive of melanoma or non-melanoma skin cancer were excised or biopsied. Histopathologic diagnosis was recorded for each of the biopsied or excised lesions.
Study: NCT02591654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Each patient will receive pembrolizumab 200mg administered as a 30 minute intravenous (IV) infusion every 3 weeks for an indefinite period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLT PET
Description: FLT PET/CT is increasingly being utilized as an early PD biomarker in cancer given the close association between FLT uptake and proliferative index.